Loading...
•
Sep 30, 2022
Anika Q3 2022 Earnings Report
Anika reported third quarter results with revenue growth of 2%.
Key Takeaways
Anika Therapeutics reported solid financial performance in the third quarter, marked by a 2% revenue growth. The company saw positive results from the X-Twist Fixation System limited launch and successful Cingal Phase III clinical trial. They are on track to achieve FY2022 guidance.
Third quarter revenue grew by 2%.
Phase III clinical trial for Cingal achieved primary endpoint.
Pivotal Phase III clinical trial for Hyalofast reached 96% enrollment.
Positive feedback from limited market release of X-Twist Fixation System.
Anika
Anika
Forward Guidance
The Company continues to expect its overall revenue for fiscal year 2022 to be toward the upper end of its guidance range of low to mid single-digit growth compared with 2021.